Group 1 - The core point of the article is that Nanwei Co., Ltd. announced that its controlling shareholder, Mr. Li Ping, has pledged part of his shares, specifically 3 million shares [2] Group 2 - The announcement was made on the evening of September 23 [2] - The pledge of shares indicates a potential change in the liquidity position of the controlling shareholder [2] - The company is subject to market scrutiny following this pledge, as it may affect investor confidence [2]

Group 1 - The core point of the article is that Jiangsu Nanfang Weicai Pharmaceutical Co., Ltd. announced significant share pledges by its controlling shareholder, Mr. Li Ping, which raises concerns about the company's financial stability and governance [1] Group 2 - As of the announcement date, Mr. Li Ping holds approximately 119 million shares, accounting for 41.12% of the company's total share capital [1] - Mr. Li Ping and his concerted actors, Mr. Li Yongping and Mr. Li Yongzhong, collectively hold about 137 million shares, representing 47.25% of the total share capital [1] - After the partial share pledge, Mr. Li Ping has pledged a total of 87.4 million shares, which is 73.54% of his total holdings and 30.24% of the company's total share capital [1] - Mr. Li Ping and his concerted actors have collectively pledged approximately 97.04 million shares, which is 71.06% of their total holdings and 33.57% of the company's total share capital [1]

一、上市公司股份质押 证券代码：603880 证券简称：南卫股份 公告编号：2025-023 江苏南方卫材医药股份有限公司关于 控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至本公告披露日，江苏南方卫材医药股份有限公司（以下简称"公司"） 控股股东李平先生持有公司股份 118,841,048 股，占公司总股本的 41.12%。公 司控股股东李平先生及一致行动人李永平先生、李永中先生合计持有公司股份 136,560,415 股，占公司总股本的 47.25%。本次部分股份质押后，李平先生累计 质押公司股份 87,400,000 股，占其持有公司股份总数的 73.54%，占公司总股本 的 30.24%，李平先生及其一致行动人李永平先生、李永中先生累计质押公司股 份97,039,338股，占其合计持有公司股份总数的71.06%，占公司总股本的33.57%。 公司于 2025 年 9 月 23 日接到公司控股股东李平先生通知，获悉其所持部分 公司股份办理质押业务，具体事项如下： 2. ...

Core Viewpoint - Nanjing South Medical Co., Ltd. (南卫股份) has experienced a stock price increase of 37.47% year-to-date, but has seen a decline of 5.23% in the last five trading days and 11.54% in the last twenty days, indicating volatility in its stock performance [2]. Company Overview - Nanjing South Medical Co., Ltd. was established on July 4, 1990, and listed on August 7, 2017. The company specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [2]. - The revenue composition of the company includes: 39.59% from adhesive bandages, 28.11% from protective products, 22.54% from adhesive tapes and bandages, 5.01% from dressings, 2.63% from first aid kits, 1.71% from other products, and 0.40% from topical agents [2]. Financial Performance - For the first half of 2025, Nanjing South Medical reported a revenue of 306 million yuan, representing a year-on-year growth of 1.39%. However, the net profit attributable to the parent company was a loss of 12.97 million yuan, a significant decrease of 1363.32% compared to the previous year [2]. - The company has distributed a total of 77.52 million yuan in dividends since its A-share listing, but has not issued any dividends in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Nanjing South Medical was 14,500, an increase of 48.53% from the previous period. The average number of circulating shares per shareholder was 19,986, a decrease of 32.67% [2]. - Notably, the index-enhanced fund 华夏中证500指数增强A (007994) has exited the list of the top ten circulating shareholders [3].

证券代码：603880 证券简称：南卫股份 公告编号：2025-022 江苏南方卫材医药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 16 日（星期四）至 10 月 22 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@nanfangmedical.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 江苏南方卫材医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 23 日（星期四） 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...

Group 1 - The company, Nanwei Co., Ltd. (603880.SH), reported a total operating revenue of 306 million yuan for the first half of 2025, representing a year-on-year growth of 1.39% [1] - The net profit attributable to shareholders of the parent company was -12.97 million yuan, compared to a net profit of 1.03 million yuan in the same period last year [1] - The basic earnings per share were -0.045 yuan [1]

Company Performance - Nanwei Co., Ltd. (SH 603880) reported a revenue of approximately 306 million yuan for the first half of 2025, representing a year-on-year increase of 1.39% [1] - The company experienced a net loss attributable to shareholders of approximately 12.97 million yuan [1] - Basic earnings per share were reported as a loss of 0.045 yuan [1] Industry Context - The domestic A-class car exhibition, featuring nearly 120 brands and 1,600 vehicles, is set to open in the second half of the year, indicating a competitive landscape in the automotive market [1] - The emergence of new energy vehicles is expected to reshape the market dynamics in the southwest region [1]

Group 1 - The company, Nanwei Co., Ltd., reported a half-year revenue of 306,075,903.06 yuan, representing a year-on-year increase of 1.39% [1] - The net profit attributable to shareholders of the listed company was -12,967,713.84 yuan, showing a year-on-year decrease of 1363.32% [1] Group 2 - Among the top ten circulating shareholders, Zhou Zhongkun is a newly added circulating shareholder [2]

Core Viewpoint - Jiangsu Nanfang Medical Co., Ltd. reported a decline in net profit for the first half of 2025, with a total revenue of approximately 306 million yuan, reflecting a slight increase of 1.39% compared to the previous year, while the net profit attributable to shareholders decreased significantly to approximately -12.97 million yuan, a drop of 1,363.32% [2][11]. Company Overview and Financial Indicators - The company operates in the medical manufacturing industry, focusing on the research, production, and sales of transdermal products, medical tapes, bandages, first aid kits, protective gear, and nursing products [5][6]. - Key financial metrics for the first half of 2025 include: - Revenue: 306,075,903.06 yuan, up 1.39% from 301,870,459.32 yuan in the same period last year - Total profit: -13,452,057.12 yuan, down 773.56% from 1,997,147.46 yuan - Net profit attributable to shareholders: -12,967,713.84 yuan, down 1,363.32% from 1,026,478.54 yuan - Net cash flow from operating activities: 35,195,110.17 yuan, up 965.49% from 3,303,181.38 yuan [2][3][11]. Industry Development and Main Business - The medical industry is a strategic sector crucial for national health and economic development, with a focus on transitioning from factor-driven to innovation-driven growth during the "14th Five-Year Plan" period [4][5]. - The company is positioned to benefit from national policies aimed at enhancing the medical equipment industry, including subsidies for innovation and technology upgrades [4][5]. - The company’s main products include transdermal products, medical tapes, bandages, first aid kits, and protective gear, with a focus on high-quality manufacturing and compliance with international standards [5][6][15]. Operational Analysis - The company employs a "sales-driven procurement" model, ensuring that raw materials are purchased based on production orders, which helps in managing costs effectively [7][8]. - The production model is primarily "order-based," allowing the company to adapt quickly to customer demands while maintaining quality control through a rigorous supplier management system [8][9]. - The company has established a strong market presence, particularly in the transdermal product segment, leveraging its experience and regional advantages to meet both domestic and international customer needs [10][17]. Financial Management and R&D - The company has invested 1,329.08 million yuan in R&D during the reporting period, focusing on improving existing products and developing new technologies, although this represents a 9.7% decrease from the previous year [12][13]. - The management emphasizes cost control across all operational aspects, aiming to enhance financial performance and reduce the asset-liability ratio [13][16].

Core Viewpoint - Jiangsu Nanfang Medical Co., Ltd. reported a decline in net profit and total profit for the first half of 2025 compared to the same period in 2024, indicating potential challenges in the company's financial performance [4]. Company Overview - The company code is 603880, and it is listed on the Shanghai Stock Exchange under the name Nanfang Medical [3]. - As of the end of the reporting period, the total assets amounted to approximately 986.99 million yuan, a decrease of 6.58% from the previous year [3]. Financial Performance - The operating revenue for the reporting period was approximately 306.08 million yuan, reflecting a slight increase of 1.39% compared to 301.87 million yuan in the same period last year [4]. - The total profit for the period was approximately -13.45 million yuan, a significant decrease of 773.56% from a profit of 1.99 million yuan in the previous year [4]. - The net profit attributable to shareholders was approximately -12.97 million yuan, down 1,363.32% from 1.03 million yuan in the previous year [4]. - The net profit after deducting non-recurring gains and losses was approximately -15.40 million yuan, a decrease of 730.84% from 2.44 million yuan in the previous year [4]. - The basic earnings per share were -0.045 yuan, a decline of 1,225.00% from 0.004 yuan in the previous year [5]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 14,462 [7]. - The largest shareholder, Li Ping, holds 41.12% of the shares, with 118,841,048 shares, of which 82,400,000 are pledged [6]. - Other significant shareholders include Xu Dong (4.48%), Li Yongping (3.33%), and Li Yongzhong (2.80%) [6].